Protocol Ledger

NCT03603288 · Phase III · TERMINATED

Phase III Study With Idebenone in Patients With Duchenne Muscular Dystrophy (SIDEROS-E)

Interventional Phase III clinical trial protocol NCT03603288 sponsored by Santhera Pharmaceuticals in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-07-04 Enrollment: 161 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03603288
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)161 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03603288
Protocol FieldVerified Registry Value
NCT IdentifierNCT03603288
Consolidated Lead SponsorSanthera Pharmaceuticals
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment161 participants (ACTUAL)
Registered Start Date2018-07-04
WhyStopped ClassificationLack of Efficacy / Futility

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI